Andros Pharmaceuticals Co.,Ltd
TWO: 6917.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ming-Wen Lee
- Headquarters
- Zhubei, Taiwan
- IPO year
- 2023
- Market cap
- NT$1.7B
- Website
- https://www.andros.com.tw
Loading 6917…
Loading profile data…Frequently asked questions about 6917
What does Andros Pharmaceuticals Co.,Ltd (6917.TWO) do?
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anestheti...
Where does 6917.TWO trade?
Andros Pharmaceuticals Co.,Ltd (6917.TWO) trades on the Taipei Exchange.
What sector is 6917.TWO in?
Andros Pharmaceuticals Co.,Ltd (6917.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Andros Pharmaceuticals Co.,Ltd?
Ming-Wen Lee is the chief executive officer of Andros Pharmaceuticals Co.,Ltd (6917.TWO).
Where is Andros Pharmaceuticals Co.,Ltd headquartered?
Andros Pharmaceuticals Co.,Ltd is headquartered in Taiwan.
Does 6917.TWO pay a dividend?
Andros Pharmaceuticals Co.,Ltd (6917.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6917.TWO go public?
Andros Pharmaceuticals Co.,Ltd (6917.TWO) completed its initial public offering in 2023.